Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)

NCT02404935 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

139

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Cetuximab
DRUG: FOLFIRI and cetuximab

Sponsor

UNICANCER